Valuation: Charles River Laboratories International, Inc.

Market Cap 13.69B 12.16B 11.37B 10.36B 19.51B 1,318B 19.78B 138B 53.26B 671B 51.41B 50.3B 2,157B P/E 2026 *
76.2x
P/E 2027 * 30.6x
Enterprise Value 15.85B 14.07B 13.16B 11.99B 22.58B 1,526B 22.89B 159B 61.64B 777B 59.49B 58.2B 2,496B EV / Sales 2026 *
4.04x
EV / Sales 2027 * 3.84x
Free-Float
95.58%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Charles River Laboratories International, Inc.

1 day-1.82%
1 week-1.28%
Current month-2.19%
1 month+4.68%
3 months+27.27%
6 months+71.18%
Current year+48.27%
1 week 254.8
Extreme 254.8
261.3
1 month 235.2
Extreme 235.2
261.3
Current year 127.95
Extreme 127.95
261.3
1 year 127.95
Extreme 127.95
261.3
3 years 87.7
Extreme 87.7
261.3
5 years 87.7
Extreme 87.7
386
10 years 59.83
Extreme 59.829
388
Manager TitleAgeSince
Chief Executive Officer 56 04/05/2026
Director of Finance/CFO 58 05/04/2026
Chief Tech/Sci/R&D Officer 45 11/01/2026
Director TitleAgeSince
Chairman 75 31/12/1999
Director/Board Member 56 04/05/2026
Chairman 69 04/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
-1.86%-1.28% - - 13.69B
+4.16%+3.04%+49.37%+94.17% 74.41B
-3.11%-3.53%+21.92%+74.60% 59.26B
+0.89%-0.63%+4.28%+34.51% 47.14B
-0.42%-4.03%+26.98%+33.83% 42.91B
+1.34%+1.71%+356.17%+696.60% 44.13B
-2.11%-2.60%+1.82%+96.90% 40.79B
-0.54%+2.93%+9.50%+50.41% 30.77B
-2.68%+5.11%+33.11%+19.50% 29.31B
+0.35%-7.32%-28.53%+330.47% 23.71B
Average -0.39%-0.64%+52.74%+159.00% 43.6B
Weighted average by Cap. +0.03%-0.40%+57.87%+150.75%

Financials

2026 *2027 *
Net sales 3.92B 3.48B 3.25B 2.97B 5.58B 377B 5.66B 39.37B 15.24B 192B 14.71B 14.39B 617B 4.01B 3.56B 3.33B 3.03B 5.71B 386B 5.79B 40.26B 15.58B 196B 15.04B 14.72B 631B
Net income 164M 146M 136M 124M 234M 15.8B 237M 1.65B 638M 8.05B 616M 603M 25.85B 431M 383M 358M 326M 614M 41.51B 623M 4.33B 1.68B 21.14B 1.62B 1.58B 67.9B
Net Debt 2.15B 1.91B 1.79B 1.63B 3.07B 207B 3.11B 21.64B 8.38B 106B 8.08B 7.91B 339B 1.71B 1.51B 1.42B 1.29B 2.43B 164B 2.46B 17.13B 6.63B 83.61B 6.4B 6.26B 269B
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Date Price Change
02/10/26 €254.80 -2.49%
01/10/26 €261.30 +0.31%
30/09/26 €260.50 +0.97%
29/09/26 €258.00 +0.94%
28/09/26 €255.60 -0.97%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
286.83USD
Average target price
305.00USD
Spread / Average Target
+6.33%

Quarterly revenue - Rate of surprise